|
|
 |
|
Viewing report
|
|
|
|
Italy Pharmaceutical Market Overview Generic penetration set to rise
Datamonitor, July 2010, Pages: 195
Introduction
The prescription pharmaceutical market in Italy was valued at $24.9 billion in 2009. Key growth drivers for branded pharma include the growing use of chronic high-value innovative treatments driven by a growing elderly population, the high proportion of the healthcare budget spent on pharmaceuticals, and a high level of brand loyalty among Italian patients.
Scope
-Overview of Italy's socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property position
-Assesses the size of Italy's pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies
-Examines Italy's generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion
-Quantifies Italy's R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis
Highlights
Due to high pharmaceutical spend driven by limited generic usage, Italy employs a range of pricing and reimbursement tools to control costs. As a result, drug prices in Italy are among the lowest in Europe, a factor which is largely behind the country's high parallel export activity.
As a result of reforms introduced in April 2009, branded pharma companies are now forced to maintain brand prices at a higher price than the first generic product to market. This is likely to increase the level of brand erosion post patent expiry.
A number of pharma players in Italy are closing or downsizing their manufacturing and/or R&D operations in an effort to reduce costs. However, the Agenzia Italiana del Farmaco is taking steps to tackle a number of issues affecting the Italian pharma industry in order to attract investment into the country, and to ensure drugs' quality and safety.
Reasons to Purchase
-Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access.
-Quantify the size and growth of the prescription pharmaceutical market in Italy, analyzing key therapy areas, brands and companies.
-Assess drivers and resistors of generic and biosimilars uptake in Italy as well as the level of erosion brands can expect to face post patent expiry.
Customers who bought this item also bought
Will Big Pharma Find Success in Generics?
Japan Pharmaceutical Market Overview Regulatory reforms will stimulate generics uptake
Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthcare landscape
Russia Pharmaceutical Market Overview Pharma companies target Russia despite the challenges it presents
Pharmaceuticals - Global Outlook
Brazil Pharmaceutical Market Overview - Expanding healthcare access drives double-digit sales growth
France Pharmaceutical Market Overview - Austerity measures will impact pharmaceutical market growth
China Pharmaceutical Market Overview
Spain Pharmaceutical Market Overview - Price cuts set to negatively impact both branded and generics companies
Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally
|
|
|
|
